● Live Tracking 375+ pre-IPO companies with institutional-grade data — updated daily. 140 in active pipeline.

Generate Biomedicines IPO Status 2026

AI-first drug company using generative biology to design novel protein therapeutics.

IndustryBiotechnology
StageSeries A
IPO StatusPrivate
Valuation$1.2B
Total Funding$150M
HeadquartersCambridge, MA
CEOMike Nally
How to Invest in Generate Biomedicines
Pre-IPO
🔔 Get Notified When Generate Biomedicines IPOs

No secondary market access for Generate Biomedicines yet. Get instant alerts when an S-1 is filed or IPO date is announced.

Get IPO Alerts →
📡 IPO Intelligence
$49/mo — Unlimited Reports + Real-Time Updates
⚡Unlimited company analysis reports — all 375+ companies
✓Real-time IPO alerts — know the moment S-1s are filed
✓Verified data updated daily — not chatbot hallucinations
💡 Tracking multiple companies? Full access pays for itself after 3 reports.
$49
per month
Subscribe Now →
Cancel anytime · Secure via Stripe
Institutional Research
$19 — Get the Complete Generate Biomedicines Analysis Brief
✓Executive summary & IPO readiness breakdown
✓Competitive positioning & funding trajectory
✓Bull / bear thesis with pricing projections
✓S-1 timeline estimate & risk assessment
$19
One-time
Secure checkout · Stripe · 24h delivery

Frequently Asked Questions

What is Generate Biomedicines's current valuation? +

Generate Biomedicines is valued at $1.2B as of December 2021.

How much total funding has Generate Biomedicines raised? +

Generate Biomedicines has raised $150M in total venture capital funding.

What sector is Generate Biomedicines in? +

Generate Biomedicines is a Biotechnology company. AI-first drug company using generative biology to design novel protein therapeutics.

What is Generate Biomedicines's IPO readiness score? +

Generate Biomedicines scores 56/100 on TechStackIPO's IPO readiness index, which evaluates funding stage, valuation trajectory, S-1 filing status, and market timing signals.